This page shows the latest paclitaxel news and features for those working in and with pharma, biotech and healthcare.
The EC approved Opdivo following positive results from the phase 3 ATTRACTION-3 trial, which investigated the PD-1 inhibitor versus chemotherapy docetaxel or paclitaxel – as a treatment for patients with
Tecentriq plus paclitaxel failed to improve progression-free survival. Roche’s hopes of extending its PD-L1 inhibitor Tecentriq into metastatic triple negative breast cancer (TNBC) have fallen flat after the ... The phase 3 Impassion131 study evaluated
The phase 3 IMagyn050 study evaluated the addition of Tecentriq (atezolizumab) to Roche’s older treatment Avastin (bevacizumab) alongside chemotherapy (paclitaxel and carboplatin) in women with advanced-stage ovarian cancer.
specifically paclitaxel. ... That could suggest the effect of efti is enhanced by some property of chemo, such as increased inflammation during treatment with paclitaxel.
Last year, Lynparza plus cediranib also failed to show a statistically significant improvement over standard chemotherapy with paclitaxel in patients with platinum-resistant ovarian cancer in the BAROCCO study, which included
The MHLW approved Opdivo based on the results from the phase 3 ATTRACTION-3 trial, which evaluated the PD-1 inhibitor versus chemotherapy – docetaxel or paclitaxel – as a treatment for patients
More from news
Approximately 9 fully matching, plus 119 partially matching documents found.
An FDA ruling on Tecentriq in combination with carboplatin and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic non-squamous NSCLC (based on the IMpower130 trial) is
Sorrento (Igdrasol)/ NantPharma. Asset acquisition. Acquisition of Igdrasol including Cynviloq (paclitaxel nanoparticle).
For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Current chemotherapy treatment options for ovarian cancer are fairly standard. After debulking surgery, the patient will undergo their first line of chemotherapy; the standard of care involves a combination of paclitaxel
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...